Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Global Pharmaceutical Company Mallinckrodt Locates Growing Specialty Brands Businesses in Bedminster

8/19/2016

0 Comments

 
Chesterfield, United Kingdom — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced yesterday it will build out a new campus for its fast-growing Specialty Brands organizations in the Somerset Financial Center, 1405-1425 Route 206, in Bedminster.

Mallinckrodt will invest greater than $80 million in New Jersey, and anticipates approximately 400 employees will occupy the new space in the first quarter of 2017.

The company is also continuing its investment in St. Louis, Mo., having recently begun the next phase of construction at its downtown St. Louis manufacturing facility—part of the more than $140 million in capital projects and related expenses it has invested in offices and plant locations that house Mallinckrodt's legacy businesses and key administrative functions in the area.

Having acquired multiple companies in 18 months, by late 2015, Mallinckrodt found itself with commercial and development operations spread across more than a dozen U.S. sites. ​

The Bedminster, N.J. campus will consolidate operations for its Specialty Brands groups, co-locating more than 400 commercial and science employees focused on marketed and development products in its autoimmune and rare diseases and hospital businesses – growth platforms the company continues to build on as indicated by its recently announced acquisition.
"As we began to transform Mallinckrodt into a specialty pharmaceutical organization, we acquired a base of established operations on the East Coast," said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt.

"With this base, and recognizing the important concentration of specialty pharmaceutical talent and intellectual capital in the area,” Trudeau added, “we believe consolidating our Specialty Brands organizations in New Jersey provides compelling value. We believe the state will be a great business destination for the company."

"Bedminster is an excellent setting for Mallinckrodt," Trudeau continued, "allowing us to design a work space that will meet the needs of our dynamic, fast-growing business, while providing an exceptional working environment to support collaboration among our employees."    

New Jersey Lt. Governor Kim Guadagno said, "I'm pleased to welcome Mallinckrodt to Bedminster and look forward to future collaboration with the company as they build their Specialty Brands business here in the Garden State.”

"New Jersey provides a favorable environment for the growth of pharmaceutical companies given the wide range of business incentives we offer and our highly skilled and educated workforce,” Lt. Governor Guadagno continued.

As also noted, Mallinckrodt continues to reinvest in St. Louis, where the company's roots date back nearly 150 years. Recent investment includes the commitment of more than $8 million for expansion of its downtown St. Louis manufacturing facility, as well as a $12 million site addition opened in mid-2015 to increase manufacturing efficiency.

"For decades, Mallinckrodt has proudly maintained a significant presence in St. Louis, where many of us continue to live and work," said Trudeau, "and we're excited to reinforce that presence in this region with continued reinvestment."

Individuals interested in exploring an open career opportunity at Mallinckrodt's New Jersey facility should visit www.mallinckrodtnortheastjobs.com.  Open positions with the company more broadly are available at www.mallinckrodt.com.

About Mallinckrodt

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.

The company's core strengths include the acquisition and management of highly regulated raw materials, and specialized chemistry, formulation and manufacturing capabilities.

The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
 
 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507